Taiji Miyake
Chugai Pharma (United States)(US)
Publications by Year
Research Areas
Coronary Interventions and Diagnostics, Cardiac Imaging and Diagnostics, Cardiac Arrhythmias and Treatments, Atrial Fibrillation Management and Outcomes, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets(2023)89 cited
- → Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism(2016)70 cited
- → Prevalence of antibodies to Coxiella burnetii in Japan(1993)52 cited
- → Comparisons of Nonhyperemic Pressure Ratios(2020)38 cited
- → Quantitative prediction of P‐glycoprotein‐mediated drug–drug interactions and intestinal absorption using humanized mice(2021)17 cited
- → Noninvasive estimation of pulmonary capillary wedge pressure in patients with mitral regurgitation: A speckle tracking echocardiography study(2015)16 cited
- → A Useful Model Capable of Predicting the Clearance of Cytochrome P450 3A4 (CYP3A4) Substrates in Humans: Validity of CYP3A4 Transgenic Mice Lacking Their Own Cyp3a Enzymes(2014)13 cited
- → Quantitative prediction of CYP3A‐mediated drug–drug interactions by correctly estimating fraction metabolized using human liver chimeric mice(2023)11 cited
- → A Case Report of Acute Myocardial Infarction Induced by Coronary Spasm(2013)8 cited
- → Quantitative Prediction of OATP-Mediated Disposition and Biliary Clearance Using Human Liver Chimeric Mice(2023)8 cited